Home LiteratureArticle Details
PMID: 20101094 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype.

The Journal of clinical investigation ·Vol. 120 ·No. 2 ·2010-02-00 ·Pages 636-44

Park SY, Gönen M, Kim HJ, Michor F, Polyak K

Abstract

Intratumor genetic heterogeneity is a key mechanism underlying tumor progression and therapeutic resistance. The prevailing model for explaining intratumor diversity, the clonal evolution model, has recently been challenged by proponents of the cancer stem cell hypothesis. To investigate this issue, we performed combined analyses of markers associated with cellular differentiation states and genotypic alterations in human breast carcinomas and evaluated diversity with ecological and evolutionary methods. Our analyses showed a high degree of genetic heterogeneity both within and between distinct tumor cell populations that were defined based on markers of cellular phenotypes including stem cell-like characteristics. In several tumors, stem cell-like and more-differentiated cancer cell populations were genetically distinct, leading us to question the validity of a simple differentiation hierarchy-based cancer stem cell model. The degree of diversity correlated with clinically relevant breast tumor subtypes and in some tumors was markedly different between the in situ and invasive cell populations. We also found that diversity measures were associated with clinical variables. Our findings highlight the importance of genetic diversity in intratumor heterogeneity and the value of analyzing tumors as distinct populations of cancer cells to more effectively plan treatments.

MeSH Terms
Antigens, CD/analysis Breast Neoplasms/genetics,pathology Cell Differentiation Chromosomes, Human, Pair 8 Disease Progression Female Genes, erbB-2 Genetic Variation Humans Hyaluronan Receptors/analysis In Situ Hybridization, Fluorescence Neoplasm Invasiveness Receptors, IgE/analysis
Chemicals
Antigens, CD Hyaluronan Receptors Receptors, IgE
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Park So Yeon
Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Gönen Mithat
Kim Hee Jung
Michor Franziska
Polyak Kornelia
References (29)
29 references, click to expand
  1. Breast tumor heterogeneity: cancer stem cells or clonal evolution?
    Cell Cycle. 2007 Oct 1;6(19):2332-8 PMID: 17786053
  2. Cytogenetic abnormalities in an in situ ductal carcinoma and five prophylactically removed breasts from members of a family with hereditary breast cancer.
    Breast Cancer Res Treat. 1996;38(2):177-82 PMID: 8861836
  3. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia.
    Science. 2008 Nov 28;322(5906):1377-80 PMID: 19039135
  4. Genetic clonal diversity predicts progression to esophageal adenocarcinoma.
    Nat Genet. 2006 Apr;38(4):468-73 PMID: 16565718
  5. Molecular definition of breast tumor heterogeneity.
    Cancer Cell. 2007 Mar;11(3):259-73 PMID: 17349583
  6. Cell type-specific DNA methylation patterns in the human breast.
    Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14076-81 PMID: 18780791
  7. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.
    Blood. 2002 Aug 1;100(3):1014-8 PMID: 12130516
  8. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis.
    Nature. 2009 May 21;459(7245):428-32 PMID: 19363473
  9. Regulation of in situ to invasive breast carcinoma transition.
    Cancer Cell. 2008 May;13(5):394-406 PMID: 18455123
  10. Intratumor heterogeneity of K-ras2 mutations in colorectal adenocarcinomas: association with degree of DNA aneuploidy.
    Am J Pathol. 1996 Jul;149(1):237-45 PMID: 8686748
  11. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
    Science. 2007 May 18;316(5827):1039-43 PMID: 17463250
  12. Resistance to imatinib: mechanisms and management.
    J Natl Compr Canc Netw. 2005 Nov;3(6):757-68 PMID: 16316612
  13. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
    JAMA. 2006 Jun 7;295(21):2492-502 PMID: 16757721
  14. Metapopulation dynamics and spatial heterogeneity in cancer.
    Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13085-9 PMID: 12351679
  15. Epigenetic patterns of embryonic and adult stem cells.
    Cell Cycle. 2009 Mar 15;8(6):809-17 PMID: 19229128
  16. Cancer as an evolutionary and ecological process.
    Nat Rev Cancer. 2006 Dec;6(12):924-35 PMID: 17109012
  17. Purification of the human NF-E2 complex: cDNA cloning of the hematopoietic cell-specific subunit and evidence for an associated partner.
    Mol Cell Biol. 1993 Sep;13(9):5604-12 PMID: 8355703
  18. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer.
    Clin Cancer Res. 2010 Feb 1;16(3):876-87 PMID: 20103682
  19. Genome-wide functional synergy between amplified and mutated genes in human breast cancer.
    Cancer Res. 2008 Nov 15;68(22):9532-40 PMID: 19010930
  20. Tumor heterogeneity: biological implications and therapeutic consequences.
    Cancer Metastasis Rev. 1983;2(1):5-23 PMID: 6616442
  21. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer.
    Lancet. 2002 Aug 31;360(9334):683-9 PMID: 12241875
  22. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution.
    Clin Cancer Res. 2008 Jan 15;14(2):370-8 PMID: 18223211
  23. Intraclass correlations: uses in assessing rater reliability.
    Psychol Bull. 1979 Mar;86(2):420-8 PMID: 18839484
  24. Stem cell concepts renew cancer research.
    Blood. 2008 Dec 15;112(13):4793-807 PMID: 19064739
  25. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.
    Blood. 2003 Jul 15;102(2):659-61 PMID: 12663457
  26. Mammary tumor heterogeneity.
    Symp Fundam Cancer Res. 1983;36:209-21 PMID: 6382505
  27. Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma.
    Am J Pathol. 1995 Oct;147(4):1112-22 PMID: 7573356
  28. Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases.
    Breast Cancer Res Treat. 2007 Apr;102(2):143-55 PMID: 16906480
  29. Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient.
    Radiology. 2001 Dec;221(3):763-7 PMID: 11719674
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
1558-8238
Published
2010-02-00
Epub
2010-00-25
Pages
636-44
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC2810089
Subset
IM
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com